title: Transitioning from malaria control to elimination: the vital role of ACTs.
abstract: Artemisinin-based combination therapies (ACTs) have been instrumental in reducing malaria burden. Many countries report geographical areas with reduced levels of endemic disease. As the transition is made from malaria control to elimination, new ways of using existing treatments are being considered. In this opinion paper, the requirements for the continued success of ACTs, their role in this transition, and possible new ways of using these drugs in an elimination setting are discussed. ACTs have an important role to play in maintaining the current success of control programs, and may also drive these successes forward into the widespread elimination of malaria.
authors.affiliation: Novartis Pharma AG, Novartis Campus, CH-4002, Basel, Switzerland. heiner.grueninger@novartis.com
authors.forename: Heiner
authors.initials: H
authors.lastname: Grueninger
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
mesh_terms: D000962:Antimalarials / Q000191:economics / Q000627:therapeutic use*; D037621:Artemisinins / Q000191:economics / Q000627:therapeutic use*; D018890:Chemoprevention; D060740:Disease Eradication / Q000191:economics / Q000592:standards; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*
chemical_list: D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin